Immuno-Oncology | Specialty

CELESTIAL Trial: Second-Line Cabozantinib's Value in HCC

February 9th 2018

REFLECT Trial: Frontline Lenvatinib's Value in HCC

February 9th 2018

Hepatocellular Carcinoma: A Changing Treatment Landscape

February 9th 2018

Dr. Hammers on the Future of Immunotherapy in RCC

February 7th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of immunotherapy for patients with renal cell carcinoma (RCC).

New Model Predicts Survival Following Treatment With Atezolizumab for Bladder Cancer

February 6th 2018

A new model based on 6 clinical factors may be able to predict overall survival for patients with advanced urothelial cancers being treated with the PD-L1 inhibitor atezolizumab.

Atezolizumab Combo Improves PFS by 3.5 Months in mRCC

February 6th 2018

The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.

Frontline Nivolumab/Ipilimumab Improves PFS in High TMB NSCLC

February 5th 2018

The combination of nivolumab and ipilimumab improved progression-free survival compared with chemotherapy in treatment-naïve patients with high tumor mutation burden non–small cell lung cancer.

Balar Addresses Advances in Bladder and Kidney Cancer

February 5th 2018

Arjun V. Balar, MD, discusses the landscape of current and future standards of care for immunotherapy in bladder and kidney cancer.

Can Immunotherapy Bypass Sequential Care in RCC?

February 2nd 2018

Despite positive clinical trial results, the role of immunotherapy in renal cell carcinoma remains unclear.

Immunotherapy Tops CRISPR Agenda

February 1st 2018

The gene-editing tool known as CRISPR may eventually enable oncology investigators to create methods for killing tumors directly, but thus far, the focus is on enhancing forms of immunotherapy already in clinical practice.

Dr. Kim on the Safety of Immune Checkpoint Inhibition in Surgical Patients With Lung Cancer

January 31st 2018

Jae Y. Kim, MD, chief, Division of Thoracic Surgery, Department of Surgery, assistant professor, Department of Surgery, City of Hope, discusses the use of immune checkpoint inhibitors in surgical patients with lung cancer.

Expert Shares Insight on Immunotherapy, Emerging Strategies in Prostate Cancer

January 30th 2018

David R. Wise, MD, PhD, discusses the promise for immunotherapy and other emerging approaches in the field of prostate cancer.

Dr. Balar on Current and Future Standards of Care in Kidney Cancer Treatment

January 30th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.

Emerging Immunotherapy Options for Metastatic NSCLC

January 30th 2018

Immunotherapy with Antiangiogenics in NSCLC

January 30th 2018

Immunotherapy in Metastatic NSCLC

January 30th 2018

PD-L1 Testing in Metastatic NSCLC

January 30th 2018

Radiotherapy Strategies in Locally Advanced NSCLC

January 30th 2018

Evolving Strategies for Locally Advanced NSCLC

January 30th 2018

Practical Considerations for Immunotherapy in Stage 3 NSCLC

January 30th 2018